EMA recommends approval of the Moderna vaccine for 12 to 17-year-olds
23 July, 2021
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the authorisation of the COVID-19 vaccine Moderna to be used in adolescents between 12 and 17 years in the European Union. Following this positive response by CHMP, the European Comission will consider authorising the Moderna vaccine for this age group.
Moderna is currently conducting a Phase 2/3 study called the KidCOVE study, which involves vaccinating children from 6 months old to less than 12 years.
English
Japanese
